DRD2 and neuroendocrine neoplasm: However, increased expression of DRD2 in a neuroendocrine tumor patient was associated with longer survival, and activation of DRD2 by the DRD2 agonist BIM53097 reduced the ability of migration and invasion of human tumorous pituitary cells (34, 60).